Revvity Sees Growth in Diagnostics, Encounters Challenges in China
Revvity (RVTY) is experiencing growth in its diagnostics and high-margin Signals Software segments, positioning it for expansion despite some short-term challenges. The company faces headwinds from reimbursement changes in China, subdued demand from academic and government sectors, and macroeconomic fluctuations, which have led to an underperformance in its stock this year. However, Revvity anticipates an average annual growth rate of 8.7% over the next five years, driven by its strong product lineup and improving business operations.
Revvity Gains on Diagnostics Strength, Faces China Headwinds
Revvity (RVTY) is experiencing growth due to its robust diagnostics segment, particularly in newborn screening and immunodiagnostics, and the expansion of its high-margin Signals Software business. However, the company faces headwinds in China due to reimbursement reforms impacting immunodiagnostics and weak academic/government demand in instrumentation, leading to a cautious growth outlook for 2026. While the Life Sciences segment shows signs of stabilization, margin pressures from tariffs, foreign exchange, and cost timing are also expected to affect profitability.
Friedland Enterprises Files Amended Schedule 13D on Lulu's Fashion Lounge Holdings (LVLU), Publishes Independent FY2026 Financial Model
Friedland Enterprises has filed an amended Schedule 13D concerning its 5% stake in Lulu's Fashion Lounge Holdings (LVLU), acknowledging recent operational progress by the company. The activist investor has revised its six-point shareholder reform platform and published an independent FY2026 financial model, projecting revenue and Adjusted EBITDA scenarios for LVLU, which it believes is significantly undervalued.
Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $108
Evercore has reiterated its Buy rating for Revvity (RVTY.US) but has reduced the target price for the company's stock to $108. This adjustment indicates a continued positive outlook on the stock's potential despite a revision in its valuation.
Revvity Sees Growth in Diagnostics, Encounters Challenges in China
Revvity, Inc. (RVTY) is experiencing growth in its diagnostics sector and robust performance from its high-margin Signals Software segment. However, the company faces significant challenges, particularly in China due to reimbursement changes, which have led to a projected decline in immunodiagnostics in the region. Despite these headwinds and conservative growth projections for 2026, analysts anticipate an upward trend in earnings per share, with increased revenue and EPS expected for Q1 2026.
Tudor Investment Corp ET AL Purchases Shares of 172,601 Revvity Inc. $RVTY
Tudor Investment Corp ET AL has initiated a new position in Revvity Inc. (NYSE:RVTY), acquiring 172,601 shares valued at approximately $15.13 million. This purchase represents about 0.15% of the company, with institutional investors now holding 86.65% of the stock. Revvity recently surpassed quarterly earnings expectations and issued a positive full-year 2026 EPS guidance, while analysts currently hold a consensus "Hold" rating with a $112.92 price target.
VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript
VolitionRx Limited (AMEX:VNRX) reported strong Q4 and full-year 2025 results, with 40% revenue growth driven by its Nu.Q Discover platform and initial sales of Nu.Q NETs products. The company highlighted significant progress in commercializing its Nu.Q platform for human diagnostics, including partnerships with Werfen and Hologic, and critical advancements in feline cancer detection and a novel Capture-Seq technology for pure circulating tumor DNA. VolitionRx is shifting its strategic focus from R&D to commercialization, aiming for multiple licensing agreements and eventual widespread adoption of its low-cost, accurate diagnostic tests for cancer and sepsis globally.
Revvity (RVTY) Valuation Check After Recent Share Price Gains And Mixed Longer Term Returns
Revvity (RVTY) has seen recent share price gains of 1.2% daily, despite a weaker longer-term performance with an 11.5% decline over the past year. One analyst target suggests the stock is undervalued by about 34% at $88.94, with a fair value estimate of $119.56, driven by expected margin expansion from product mix shifts and cost actions. However, its current P/E ratio of 41.5x is higher than the industry average, raising questions about whether expectations are already priced in, alongside potential risks from China reimbursement policies and funding changes.
Revvity, Inc. (RVTY) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.
Revvity Inc. stock outperforms competitors on strong trading day
Revvity Inc. (RVTY) saw its stock rise by 1.16% on Thursday, closing at $88.94. This performance outpaced the broader market, as the S&P 500 Index gained 0.11% while the Dow Jones Industrial Average declined by 0.13%. This marks Revvity's fourth consecutive day of stock gains.
Baird Maintains Revvity (RVTY) Outperform Recommendation
This article states that Baird has maintained its "Outperform" recommendation for Revvity (RVTY). It does not provide any further details or analysis regarding this recommendation.
Here’s Artisan Mid Cap Value Fund’s Investment Thesis for Revvity (RVTY)
Artisan Mid Cap Value Fund, in its fourth-quarter 2025 investor letter, highlighted its investment in Revvity, Inc. (NYSE: RVTY), a life sciences and diagnostics company. The fund's thesis focuses on Revvity's streamlined structure post-spin-off from PerkinElmer, high recurring revenue, and strong growth prospects, particularly within its BioLegend reagents and Signals software platform. Despite recent stock losses, Artisan views Revvity as an attractive risk-reward opportunity due to its discount to peers and active share repurchases.
Liquidity Mapping Around (RVTY) Price Events
This article, published on April 1, 2026, analyzes Revvity Inc. (NASDAQ: RVTY) using AI models, highlighting a weak near-term sentiment despite an exceptional 37.6:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths with corresponding support and resistance levels for RVTY.
Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’
Revvity's CEO acknowledged challenges in the immunodiagnostics business in China, but attributed the stock drop to an overreaction by retail investors. This suggests the company is facing headwinds in a key market, potentially impacting future performance, while management seeks to reassure investors about its long-term prospects despite the short-term volatility.
Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’
Revvity's CEO, Prahlad Singh, acknowledged significant challenges in the company's immunodiagnostics business in China, attributing them to continued pricing pressure and slower than expected recovery. Despite the CEO's concerns, an analyst from William Blair views the subsequent 10% stock drop as an overreaction, maintaining an "Outperform" rating for the stock. This suggests a belief that the market's reaction to the news might be disproportionate to the actual long-term impact on the company.
Parkwalk leads $3.8m investment in Cavendish Laboratory spin-out Semarion
University of Cambridge spin-out Semarion has secured $3.8 million in funding, led by Parkwalk, to expand and scale manufacturing of its SemaCyte® platform. This platform enables the use of adherent cell models as assay-ready, barcoded reagents, aiming to improve flexibility, data richness, and scalability in drug discovery. The investment will support Semarion's commercial growth and broader adoption of its technology within the pharmaceutical industry.
Revvity (NYSE:RVTY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. analysts have cut their price target for Revvity (NYSE:RVTY) from $105.00 to $96.00, maintaining a "neutral" rating with a potential upside of 11.61%. Despite this, the stock has a consensus "Hold" rating from multiple analysts, with an average target price of $112.92. Revvity recently reported strong quarterly earnings, beating EPS estimates and setting optimistic FY2026 guidance.
Revvity price target lowered to $96 from $105 at JPMorgan
JPMorgan has reduced its price target for Revvity (RVTY) from $105 to $96, while maintaining a Neutral rating on the shares. This adjustment comes as JPMorgan updated its models within the life science tools and diagnostics sector. The article also notes other recent analyst actions on Revvity, including an upgrade from Sell to Hold by Nephron Research and price target increases by Baird, TD Cowen, and Evercore ISI.
J.P. Morgan Initiates Revvity(RVTY.US) With Hold Rating, Announces Target Price $96
J.P. Morgan has initiated coverage on Revvity (RVTY.US) with a Hold rating. The firm has set a target price of $96 for the company's shares. This initiation and price target suggest a neutral outlook from J.P. Morgan regarding Revvity's stock performance.
RVTY Stock News Today | Earnings, Events & Price Alerts
This page provides a comprehensive overview of recent news and events related to Revvity (RVTY) stock, including its current trading performance and links to detailed financial analysis. The news highlights include reports on Q4 2025 earnings which exceeded expectations, the company's performance amid healthcare sector trends, and various earnings insights. The article also mentions future growth projections and previous earnings analyses.
Revvity Inc (RVTY) Shares Gap Down to $83.9 on Mar 30
Revvity Inc (RVTY) shares experienced a 3.70% decline in mid-day trading on March 30, closing at $83.90 after hitting an intraday low of $83.80. This places RVTY significantly below its 52-week high but slightly above its 52-week low. Wall Street analysts maintain an "Outperform" status for RVTY, projecting an average price target of $118.32, indicating a potential upside of over 41%.
Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains
Revvity Inc. (RVTY) shares rose 1.05% to $84.78 on Monday, ending a two-day losing streak, despite a mixed trading session for the broader market. The Dow Jones Industrial Average saw a modest gain, while the S&P 500 Index experienced a slight decline. Despite its daily gains, Revvity Inc.'s stock underperformed compared to its competitors.
In-Depth Examination of Segments, Industry Developments, and Key Competitors in the Biobank Equipment Market
The biobank equipment market is projected to reach $6.5 billion by 2030, growing at a CAGR of 9.2%, driven by automation, AI integration, and the needs of regenerative medicine. Key trends include AI-powered sample management and IoT-enabled monitoring, with top players like Thermo Fisher Scientific and Merck KGaA leading innovation. The market is segmented by product type, sample type, storage system type, application areas, and end-user groups, with a focus on sustainable, automated solutions for secure and efficient biological sample preservation.
Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap
Revvity (NYSE:RVTY) is preparing for its annual meeting on April 28, 2026, where shareholders will vote on key proposals including a bylaw change allowing holders of 25% of shares to call special meetings and activist-backed tighter executive stock retention requirements. The article highlights that Revvity's shares are significantly undervalued compared to analyst targets and Simply Wall St's fair value, despite recent momentum showing a 14% decline over 30 days. These votes are crucial as they will influence shareholder power, executive incentives, and the company's future corporate actions, especially given potential risks related to large one-off items affecting earnings.
SG Americas Securities LLC Boosts Stock Holdings in Revvity Inc. $RVTY
SG Americas Securities LLC significantly increased its stake in Revvity Inc. (NYSE:RVTY) by 186.8% in Q4 2025, now holding 123,173 shares valued at $11.92 million. Other institutional investors also adjusted their positions, with large increases from EdgePoint Investment Group Inc., Norges Bank, Allspring Global Investments Holdings LLC, Dimensional Fund Advisors LP, and Invesco Ltd. Analysts currently give RVTY an average "Hold" rating with an average price target of $113.67, though some firms have raised their price targets while one downgraded it to "Sell."
Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap
Revvity (NYSE:RVTY) is holding its annual meeting on April 28, 2026, where shareholders will vote on a bylaw change allowing holders of 25% of shares to call special meetings and on activist-backed proposals for executive stock retention. These votes, alongside the company's current valuation gap and recent stock decline, will determine the balance between board flexibility and shareholder influence. The article highlights that Revvity's shares are trading significantly below analyst targets and Simply Wall St's estimated fair value.
Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap
Revvity (NYSE:RVTY) will hold its annual meeting on April 28, 2026, where shareholders will vote on a bylaw change allowing holders of 25% of shares to call special meetings and on activist-backed proposals for stricter executive stock retention. These votes are crucial for investor influence over company decisions and executive incentives, especially given Revvity's current valuation gap and recent stock decline. Investors are encouraged to monitor turnout and voting splits to understand the shifting balance of power between the board and shareholders.
Vanguard disaggregates holdings; Revvity (RVTY) filing shows 0 shares
The Vanguard Group has filed an amended Schedule 13G/A for Revvity (RVTY), disclosing 0 shares beneficially owned, representing 0% of the common stock. This filing indicates an internal realignment within Vanguard, where certain subsidiaries will now report beneficial ownership separately, as permitted by SEC Release No. 34-39538. The amendment clarifies a change in reporting structure rather than a change in underlying share counts.
Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks
This article provides a Q4 rundown of Sotera Health Company (NASDAQ:SHC) and other research tools & consumables stocks, highlighting their financial performance and market reception. Sotera Health exceeded analysts' expectations with strong revenues and a positive outlook, despite a subsequent stock dip. The article also reviews top performers like Bio-Techne and notes the weakest, Mettler-Toledo, while touching on broader market shifts driven by AI and geopolitical events.
Stifel maintains a hold rating on Revvity (RVTY)
Stifel has reiterated its Hold rating on Revvity (RVTY). The article provides no further details on the reasons behind this rating or any financial analysis of the company.
Stifel Maintains a Hold Rating on Revvity (RVTY)
Stifel maintained a Hold rating on Revvity (RVTY) with a $110 price target following a meeting with management. Revvity’s management expressed cautious optimism for 2026, forecasting low-single-digit growth in pharma and biotech, similar to 2025, driven by positive indicators such as increased high-content screening activity and improved biotech funding, but tempered by weak academic demand and short-term organic growth headwinds. The firm believes 2026 is a crucial year where macroeconomic recovery or accelerated biotech funding could lead to upside.
Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks
This article provides a Q4 rundown of research tools & consumables stocks, focusing on Sotera Health Company (SHC) and comparing its performance to peers like Bio-Techne (TECH), Mettler-Toledo (MTD), Revvity (RVTY), and Thermo Fisher (TMO). Sotera Health exceeded revenue and EPS guidance, performing strongly despite a subsequent stock dip. The sector as a whole met revenue expectations but has seen share price declines post-earnings.
Revvity Inc. Stock: Navigating Life Sciences Headwinds and Q4 Earnings Pressure Ahead
Revvity Inc. shares are under pressure due to a life sciences sector slowdown, with investors anticipating the Q4 earnings report for signs of recovery in research funding and biopharma spending. Despite a flat year-over-year revenue in Q4 2025, the Diagnostics segment showed strength, offsetting declines in Discovery & Surety, while strategic acquisitions and a focus on recurring revenue streams provide resilience. The company's valuation is near historical averages, and its blend of diagnostics services and discovery tools offers balanced risk for North American investors.
Q4 Research Tools & Consumables Earnings: Bio-Techne (NASDAQ:TECH) Earns Top Marks
Bio-Techne reported strong Q4 results, exceeding analyst expectations for revenue, though its stock saw an 18.5% decline post-reporting. The broader research tools & consumables sector had a satisfactory Q4, with revenues beating estimates by 1.2%, but share prices for many companies in the sector declined significantly. The article also reviews Q4 performance for other companies like Revvity, Mettler-Toledo, Sotera Health Company, and Agilent, highlighting varying results and market reactions amidst shifting market anxieties from AI disruption to geopolitical risks.
Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom
Revvity Inc. is facing pressure due to a slowdown in the life sciences sector, marked by reduced research funding and biopharma spending cuts, which led to flat Q4 revenue and organic declines. US investors should monitor the upcoming Q4 results for insights into NIH funding impacts, biopharma R&D recovery, and the integration of acquisitions like BioLegend, especially given the company's significant US customer base and the resilience of its diagnostics segment. Despite sector headwinds, the company's services business provides stability, while its valuation and strategic acquisitions offer potential upside for growth-seeking investors.
10 Best Mid Cap Value Stocks to Buy in 2026
The article highlights XP Inc. (NASDAQ: XP) as one of the best mid-cap value stocks to buy in 2026, based on a recent analyst rating. Itau BBA raised its price target for XP Inc. to $22 and maintained a Market Perform rating, citing strong retail equity volume growth and expected FGC reimbursement reinvestment boosting revenues. XP Inc. offers diverse investment, credit, and pension products through its technology-enabled platform.
Research Alert: CFRA Maintains Buy Rating On Shares Of Revvity, Inc.
CFRA has reiterated its Buy rating on Revvity, Inc. shares. This indicates the firm's positive outlook on the company's stock performance.
10 Best Mid Cap Value Stocks to Buy in 2026
This article, part of a larger list, focuses on Revvity, Inc. (NYSE:RVTY) as one of the best mid-cap value stocks to buy in 2026. Stifel maintained a Hold rating on the company with a $110 price target, following management's cautious yet optimistic outlook for 2026, driven by steady-state pharma/biotech growth and positive indicators despite some short-term headwinds like weak academic demand and China's market. Revvity offers advanced health science solutions across various segments.
10 Best Mid Cap Value Stocks to Buy in 2026
This article identifies Revvity, Inc. (NYSE:RVTY) as one of the best mid-cap value stocks for 2026, citing its health science solutions and moderate hedge fund interest. Stifel maintained a Hold rating on Revvity with a $110 price target, noting management's cautious optimism for moderate growth in pharma and biotech, despite some short-term headwinds like weak academic demand and slower software renewals. The firm views 2026 as pivotal for Revvity, with potential upside driven by macro-economic recovery or increased biotech funding.
Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test
Revvity Inc. is facing stock pressure due to a slowdown in the life sciences sector, with flat Q4 revenue and organic declines in research tools. Despite resilience in its diagnostics segment and strategic acquisitions like BioLegend, the company's performance is sensitive to federal funding cycles and biopharma R&D spending. US investors are monitoring its upcoming full-year 2026 guidance and the integration of new acquisitions, viewing it as a value opportunity given its current valuation and defensive service revenue.
Revvity Inc. stock faces pressure amid life sciences sector slowdown and acquisition integration cha
Revvity Inc. is experiencing pressure due to softening demand in the diagnostics and research markets, as well as challenges integrating recent acquisitions like BioLegend. Despite reaffirming full-year 2026 guidance, investors are skeptical given a 2.1% stock dip post-earnings and the broader sector's struggles post-pandemic. The company's Enterprise Services segment, focusing on newborn screening, provides some stability, while its stock trades at a discount, offering potential for patient investors betting on a life sciences recovery.
Revvity Inc. stock outperforms competitors on strong trading day
Revvity Inc. (RVTY) shares rose 1.42% to $87.16 on Monday, outperforming its competitors and the broader market. This marked the third consecutive day of gains for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw significant gains during the trading session.
Tudor Investment Corp ET AL Acquires New Shares in Revvity Inc. $RVTY
Tudor Investment Corp ET AL recently acquired a new position of 172,601 shares, valued at approximately $15.13 million, in Revvity Inc. Institutional investors now own about 86.65% of Revvity stock. The company exceeded quarterly earnings estimates and provided optimistic FY2026 guidance, while analyst ratings are mixed, with a consensus "Hold" rating and a target price of $113.67.
Reassessing Revvity (RVTY) Valuation After Strong Q4 Results And Weaker Guidance Versus Peers
Revvity (RVTY) is facing a reassessment of its valuation following strong Q4 results but weaker guidance compared to peers, coupled with new governance efforts. Despite trading well below recent highs and appearing 28.1% undervalued based on one narrative ($119.56 fair value), its current P/E ratio of 40.1x is significantly higher than its fair ratio and peer averages, indicating potential valuation risk. Investors are encouraged to review assumptions and consider other investment opportunities in healthcare technology.
Reassessing Revvity (RVTY) Valuation After Strong Q4 Results And Weaker Guidance Versus Peers
Revvity (RVTY) is experiencing volatility after strong Q4 results were followed by weaker peer comparisons and new governance efforts. Despite trading well below recent highs with a significant 1-year decline, the company's valuation narrative suggests it is 28.1% undervalued with a fair value of $119.56 due to expected margin expansion from a shifting product mix. However, a high P/E ratio of 40.1x, above both its fair ratio and peer average, indicates potential valuation risk.
Revvity Inc. stock faces pressure amid life sciences slowdown and acquisition integration challenges
Revvity Inc. reported mixed Q4 2025 results, with its diagnostics segment flatlining and overall revenue slightly missing analyst expectations, leading to an 8% stock drop. The company's conservative 2026 outlook, citing macro headwinds, further pressured shares despite strong operational discipline and progress on acquisition integration. While long-term prospects in precision medicine are positive, investors are wary of near-term growth challenges and increased competition.
Revvity Inc. stock faces pressure amid life sciences slowdown and acquisition integration challenges
Revvity Inc. reported mixed Q4 2025 results, with revenue growth stalling in its diagnostics segment, leading to an over 8% drop in its NYSE stock price. While the company's Discovery & Analytical Solutions segment showed growth, conservative 2026 revenue guidance and ongoing integration challenges from its BioLegend acquisition are creating investor uncertainty. The article highlights the importance for DACH investors to monitor Revvity's European healthtech exposure and acquisition progress.
Revvity, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators
Revvity, Inc. has seen a decline in its stock price and performance compared to the S&P 500 over the past year, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. Technical indicators show a mixed performance, with bearish trends on some metrics and mildly bullish on others. The stock's current price is $85.76, significantly down from its 52-week high.
JPMorgan Chase & Co. Grows Stock Holdings in Revvity Inc. $RVTY
JPMorgan Chase & Co. increased its stake in Revvity Inc. by 15.2% during the third quarter, bringing its total holdings to 511,360 shares valued at approximately $44.82 million. Revvity exceeded quarterly earnings expectations with $1.70 EPS on $772.06M revenue and provided a positive FY2026 EPS guidance. While analysts have a mixed "Hold" consensus rating with an average target of $113.67, the stock trades at $85.88 and offers a 0.3% dividend yield.
Revvity targets 2%-4% organic growth for 2025 as China diagnostics faces new policy headwinds
Revvity is targeting 2%-4% organic revenue growth in 2025 across its various business segments, with specific goals for diagnostics, life sciences, and applied markets. However, the company is facing new policy headwinds in China that are impacting its diagnostics business. Despite these challenges, Revvity anticipates returning to consistent organic growth in 2025.
